Xenetic Biosciences, Inc. revenue
Xenetic Biosciences, Inc.'s revenue was $3.0m in fiscal 2025, up 19.0% on the year before. Since fiscal 2012 ($293,603) it has grown at a compound 19.5% a year. Over the last twelve months it was $3.3m.
Revenue history
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 294 | 1,000 | 0 | 0 | 3,000 | 7,585 | 0 | 17 | 437 | 1,161 | 1,707 | 2,540 | 2,500 | 2,976 | 3,261 |
| Growth on the year before | — | +240.6% | −100.0% | — | — | +152.8% | −100.0% | — | +>999% | +165.6% | +47.1% | +48.8% | −1.6% | +19.0% | — |
| Gross profit | 249 | 1,000 | 0 | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Xenetic Biosciences, Inc. | $3.3m | 33.3% | 14.7% |
| Upstream Bio, Inc. | $3.2m | 16.0% | — |
| Aligos Therapeutics, Inc. | $3.7m | 19.4% | -5.5% |
| Dyadic International Inc | $3.8m | -8.0% | 3.4% |
| DBV Technologies S.a. | $3.8m | -31.6% | -11.6% |
| Camp4 Therapeutics Corp | $4.2m | 40.2% | — |
Compare with peers
- Upstream Bio, Inc. revenue
- Aligos Therapeutics, Inc. revenue
- Dyadic International Inc revenue
- DBV Technologies S.a. revenue
- Camp4 Therapeutics Corp revenue
Head to head: UPB vs XBIOALGS vs XBIODYAI vs XBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies